Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17810782 | 1.00 | FABP5 (0.46) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL29908645 | 1.00 | FABP5 (0.46) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL29444572 | 1.00 | FABP5 (0.46) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL30510263 | 1.00 | FABP5 (0.46) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL29855002 | 1.00 | FABP5 (0.46) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL16095352 | 1.00 | FABP5 (0.46) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL29378715 | 1.00 | FABP5 (0.46) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL120099 | 1.00 | FABP5 (0.46) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL120596 | 1.00 | FABP5 (0.46) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL30522085 | 0.95 | FABP5 (0.43) | FABP5FABP7KMT2ACASP3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4512818-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-02-26 | — | — | EP | disclosed |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-16 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| EP-4309741-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-114956926-B | Method for rapidly converting carboxylic acid compounds into amide and/or ester | 中国科学院兰州化学物理研究所 | 2023-08-11 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20220348558-A1 | INHIBITORS OF ENCEPHALITIC ALPHAVIRUSES | UT RESEARCH FOUNDATION | 2022-11-03 | — | — | US | disclosed |
| CN-114956926-A | Method for quickly converting carboxylic acid compounds into amides and/or esters | 中国科学院兰州化学物理研究所 | 2022-08-30 | — | — | CN | disclosed |
| US-8252895-B2 | Cyclic peptide compounds | ASTELLAS PHARMA INC. (JP) | 2012-08-28 | — | — | US | disclosed |
| EP-2455098-A1 | New cyclic peptide compounds | Astellas Pharma Inc. (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-20110073977-A1 | AMINO ACID GENERATOR AND POLYSILOXANE COMPOSITION CONTAINING THE SAME | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-03-31 | — | — | US | disclosed |
| US-7872097-B2 | Cyclic peptide compounds | ASTELLAS PHARMA INC. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100286033-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100120672-A1 | CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20090170755-A1 | Cyclic Peptide Compounds | ASTELLAS PHARMA INC. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2008-10-02 | — | — | US | disclosed |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2008-10-02 | — | — | US | disclosed |
| US-7417028-B2 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348558-A1 | INHIBITORS OF ENCEPHALITIC ALPHAVIRUSES | NEFM, EIF2AK2, PMP22 | FABP5 3375/4885FABP7 159/4885KMT2A 4155/4885 |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | FABP5 4094/4885FABP7 4602/4885KMT2A 3145/4885 |
| US-20100120672-A1 | CYCLIC PEPTIDE COMPOUNDS | VIP, HAVCR2, ZC3HAV1 | FABP5 3563/4885FABP7 4074/4885KMT2A 3600/4885 |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | KRAS, HRAS, NRAS | FABP5 4703/4885FABP7 4408/4885KMT2A 1822/4885 |
| US-20090170755-A1 | Cyclic Peptide Compounds | VIP, HAVCR2, EIF2AK2 | FABP5 3596/4885FABP7 3965/4885KMT2A 3969/4885 |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, GIPR, IAPP | FABP5 791/4885FABP7 1475/4885KMT2A 3518/4885 |
| US-20110073977-A1 | AMINO ACID GENERATOR AND POLYSILOXANE COMPOSITION CONTAINING THE SAME | DAO, BCAT1, BCAT2 | FABP5 3888/4885FABP7 3976/4885KMT2A 266/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | FABP5 4026/4885FABP7 4376/4885KMT2A 4757/4885 |
| US-20100286033-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | VIP, HAVCR2, EIF2AK2 | FABP5 3502/4885FABP7 4235/4885KMT2A 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.